SCHEMBL8433587

SCHEMBL8433587

CCNC(=O)CNCCN(C)C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DNM1 Q05193 2/20 0.44
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
KDM4E B2RXH2 2/20 0.39
ANPEP P15144 1/20 0.37
MCL1 Q07820 1/20 0.36
CA1 P00915 2/20 0.35
CA2 P00918 2/20 0.35
CA12 O43570 1/20 0.35
CA9 Q16790 1/20 0.35
FAAH O00519 1/20 0.35
ALDH1A1 P00352 1/20 0.35
MEN1 O00255 1/20 0.34
APAF1 O14727 1/20 0.34
AGTR1 P30556 1/20 0.34
RAD52 P43351 1/20 0.34
UBE2N P61088 1/20 0.34
KMT2A Q03164 1/20 0.34
PRMT3 O60678 1/20 0.34
CARM1 Q86X55 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13705057 0.89 KDM4E (0.50) DNM1KDM4EALDH1A1MEN1KMT2A
Hydrochloric Acid SCHEMBL26115945 0.82 DNM1 (0.51) DNM1CYP2C19KDM4ECA1CA2
SCHEMBL9192136 0.79 MCL1 (0.39) KDM4EMCL1FAAHALDH1A1MEN1
SCHEMBL1844564 0.79 PRMT3 (0.42) DNM1CYP2C9CYP2C19KDM4EANPEP
SCHEMBL12268125 0.79 FAAH (0.45) MCL1FAAHMEN1KMT2APAOX
SCHEMBL8429840 0.77 MCL1 (0.40) MCL1FAAHALDH1A1MEN1KMT2A
SCHEMBL18515892 0.76 GAA (0.41) CYP2C19KDM4EMCL1FAAHMEN1
SCHEMBL1790228 0.75
SCHEMBL15220629 0.75 FAAH (0.42) KDM4EMCL1CA1CA2CA12
SCHEMBL22018338 0.75 FAAH (0.42) KDM4EMCL1FAAHMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040082578-A1 Arylindenopyridines and related therapeutic and prophylactic methods ORTHO-MCNEIL PHARMACEUTICAL, INC. 2004-04-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040082578-A1 Arylindenopyridines and related therapeutic and prophylactic methods ADORA2A, ADORA1, PDE2A DNM1 3010/4885CYP2C9 1084/4885CYP2C19 903/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.